Perhaps my head is in the sand, but I do not feel thrice weekly will be an issue. As with all drugs of this nature, market share will be driven by pricing and PBMs. PBMs and insurance plan design will drive patients to generic Copaxone. The convenience of thrice weekly will lose out to member co-pay costs.
Market Data 
Markets 
AI
